Weiming Li

11PUBLICATIONS
18CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 17, 2026
Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Fang Cheng, Yu Wang, Yunfan Yang

|Mar 10, 2026
Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.

Fang Cheng, Yu Zhu, Bingcheng Liu

|Feb 10, 2026
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.

Fang Cheng, Fan Wang, Zheng Cui

|Aug 13, 2025
Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.

Mengyao Yuan, Yanli Zhang, Bingcheng Liu

|Jul 08, 2025
Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes.

Yingling Zu, Xipeng Yue, Xinrong Zhan

|Nov 26, 2024
Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy.

Lu Yu, Weiming Li, Na Xu

Pageof 2

Frequent Collaborators

5 joint publications

Fang Cheng

4 joint publications

Qian Jiang

2 joint publications

Suning Chen

2 joint publications

Zhenfang Liu